Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Safety of Regorafenib in Patients With Refractory Primary Bone Tumors

NCT05395741 is registered in ClinicalTrials.gov with Institute of Mother and Child, Warsaw, Poland as lead sponsor.

NCT NCT05395741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05395741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Safety of Regorafenib in Patients With Refractory Primary Bone Tumors
Lead sponsor
Institute of Mother and Child, Warsaw, Poland
Phase
Phase 1/2
Overall status
Completed
Start date
April 28, 2022
Completion date
June 30, 2026
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma of bone, osteosarcoma